FDA's approvals in the past week included its first new molecular entity approval in the month of June, The Medicines Co.'s Kengreal. Two more NMEs have user fee goals coming up in early July.
Keeping Track also noted the clearance of an sNDA expanding use of Eisai Inc.'s antiepileptic drug Fycompa and a...